Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection

Publicly, the company maintains confidence in its drug. It’s not clear why

Molly Ferguson/STAT

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Capricor Therapeutics is trying to stave off the Food and Drug Administration’s near-certain rejection of its cell therapy for Duchenne muscular dystrophy by submitting results from an open-label extension of its failed Phase 3 study.

Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection

Other newsrooms on this story

Related reading

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Other newsrooms on this story

Related reading

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

FDA expert panel recommends against approval of Capricor’s Duchenne drug

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Duchenne cell therapy voted down by FDA panel

FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review…